Pulmonary Hypertension Clinical Research Trials

Principal Investigator: Dr. Ben deBoisblanc

Louisiana State University Health Sciences Center Department of Medicine, Section of Pulmonary/Critical Care Medicine is currently conducting 2 clinical trials for the management of Pulmonary Hypertension.

For information on any of our clinical trials, please contact our clinical research coordinators at (504)-412-1676.

A Multi-National, Multi-Center, Randomized, double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimized Dose of Sildenafil (20, 40, or 80 mg Sildenafil TID) based on Toleration, when used in combination with intravenous prostacyclin (epoprostenol) in the treatment of pulmonary arterial hypertension.

This clinical research trial is to determine the safety and effectiveness of sildenafil (Viagra®) as an add on therapy in treating symptoms of pulmonary arterial hypertension in patients who are currently on intravenous Flolan®.

To be included in this study you must:

  1. Have Pulmonary Arterial Hypertension
  2. Have been and are currently being treated with continuous intravenous prostacyclin (Flolan®) for the past 3 months
  3. Have not previously used sildenafil as an adjunctive therapy for pulmonary hypertension

If you would like more information regarding this trial, please contact Paula Lauto, RN at 504-412-1676

A long-term, open-label study to evaluate the safety of Sitaxentan Sodium Treatment in patients with Pulmonary Arterial Hypertension

This is a clinical research study designed to evaluate an investigational medication for the treatment of pulmonary arterial hypertension.

To be included in this clinical trial you must:

  1. Have symptomatic pulmonary arterial hypertension (not caused by thromboembolism or blood clots to the lung)
  2. Not have obstructive sleep apnea
  3. Not have liver or kidney disease

If you would like more information regarding this trial, please contact Chris Glynn, RN at 504-412-1676